Stay updated with breaking news from Selective Inhibitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective, dual inhibitor of PDE3 and...
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month […]
NEWTON, Mass., April 1, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript February 26, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-1.14 EPS, expectations were $-0.86. Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day […]
Karyopharm Therapeutics Inc. (KPTI.NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Karyopharm Therapeutics Inc. | Nasdaq: KPTI | Nasdaq